Phase II trial of N-methylformamide in advanced renal cancer.

Abstract

N-methylformamide (NMF) (800-1,000 mg/m2 i.v. day 1) was given to 14 patients with measurable, advanced renal cell carcinoma in this Phase II trial. Treatment was repeated every 28 days. Significant toxicities included drug-induced hepatitis along with moderate nausea and vomiting. No objective responses were seen although several patients had stable disease with treatment for prolonged periods. NMF is not an active agent in renal cell cancer when administered by this schedule.

• Authors: J S Abrams, N Tait, H Silva, M Eisenberger, D A Van Echo, I N Olver, J Aisner
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 12 Issue 1 Pg. 41-2 (Feb 1989) ISSN: 0277-3732 [Print] United States
• PMID: 2912020 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Formamides
• methylformamide

Topics

• Adult
• Aged
• Carcinoma, Renal Cell (drug therapy)
• Chemical and Drug Induced Liver Injury (etiology)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Formamides (administration & dosage, adverse effects, therapeutic use)
• Humans
• Kidney Neoplasms (drug therapy)
• Male
• Middle Aged
• Time Factors